Velano Vascular nets $17M to roll out needle-free blood draw

The PIVO vascular access device is a single-use, disposable device that attaches to a peripheral IV line and allows for needle-free blood draws.

Velano Vascular raised $17 million in financing, which it will put toward scaling and commercializing its line of vascular access devices. The company scored FDA clearance for its second-generation, needle-free blood draw device last week.

Inpatient blood draws are one of the most common invasive medical procedures, with more than 400 million conducted in the U.S. each year, Velano said in a statement. The company’s PIVO device attaches to the peripheral IV line that most hospital inpatients already have, eliminating the need for repeated needle sticks.

While the benefits to the patient are obvious, the PIVO device also minimizes practitioners' exposure to needles and lowers the risk of practitioner injury, the company said.

The MedTech Conference

The MedTech Conference: September 23-25, Boston, MA

With over 3,000 attendees from 35 countries, The MedTech Conference features world-class plenary speakers, cross-cutting educational programming and business development opportunities. This is a prime opportunity to network, conduct business and share insights with medtech leaders. Register before July 26th and save $200!

The single-use, disposable device works by advancing a small, flexible catheter through the IV line. From here, it can draw lab-quality blood samples. Since gaining FDA clearance and a CE mark for the original PIVO in 2015, Velano has partnered with multiple health systems to deploy the device in clinical studies or in pilot programs.

“Tens of thousands of PIVO draws across multiple health systems in the U.S. and overseas reflect that there is a better, more efficient way to draw blood,” said CEO Eric Stone in the statement. “This funding will allow us to meet the growing commercial demand and to touch millions of lives in the years ahead.”

Two new unnamed investors joined existing backers, which include First Round Capital, Kapor Capital, Sutter Health, The Children’s Hospital of Philadelphia and White Owl Capital.

Meanwhile, Seventh Sense Biosystems is rolling out its own blood collection device, which uses an array of microneedles and vacuum pressure to draw blood in a “virtually painless” way.

Suggested Articles

Eisai showed correlations between amyloid biomarkers in the blood and cerebrospinal fluid, bringing it closer to a simple blood test for Alzheimer’s.

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets.